NHS-MAG3在放射性药物标记中的应用

Application of NHS-MAG3 in the radioparmaceuticals labeling

  • 摘要: 随着分子核医学的迅速发展,一种有效标记蛋白质、小分子肽和DN A寡核苷酸的双功能螯合剂NHS-MAG3(巯基乙酰三甘氨酰-N-羟基丁二酰亚胺酯)应运而生。研究表明,利用NHS-MAG3进行99Tcm标记,得到的标记物的标记率和比放射性高,体内外稳定性好,与血清蛋白的非特异结合低,为核医学提供了多种具有广阔临床应用前景的诊断和治疗的放射性药物。

     

    Abstract: With the rapid development of molecular nuclear medicine, N-hydroxysuccinimidyl S-acetylmercap-toacetyltriglycline (NHS-MAG3) as one effective bifunctional chelator has been used to radiolabel proteins, small peptides and DNA oligonucleotides with 99Tcm. The lable by the MAG3-labeling method show high labeling efficiencies and high specific activities and hold desirable stability in vitro and in vivo. The binding of the lable with plasma protein is low. So many potentially useful radioparmaceuticals for diagnosis and therapy may be produced via the NHS-MAG3 method.

     

/

返回文章
返回